Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: Findings of a prospective pilot study
Objective To conduct a prospective pilot study to determine whether macrophage targeting by 11C‐(R)‐PK11195 positron emission tomography (PET) can visualize subclinical synovitis in arthralgia patients who have anti–citrullinated protein antibodies (ACPAs). Methods Twenty‐nine arthralgia patients wh...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 64; no. 1; pp. 62 - 66 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.01.2012
Wiley Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
To conduct a prospective pilot study to determine whether macrophage targeting by 11C‐(R)‐PK11195 positron emission tomography (PET) can visualize subclinical synovitis in arthralgia patients who have anti–citrullinated protein antibodies (ACPAs).
Methods
Twenty‐nine arthralgia patients who were positive for ACPAs but did not have clinical arthritis were studied. High (spatial)–resolution 11C‐(R)‐PK11195 PET scans of the hands and wrists were performed. For all metacarpophalangeal, proximal interphalangeal, and wrist joints (i.e., 22 joints per patient), tracer uptake was scored semiquantitatively (0–3 scale) by 2 observers who were blinded with regard to the clinical data. Patients were followed up prospectively for 24 months to investigate the development of clinical arthritis.
Results
Overall agreement and kappa values for the readings of the 2 observers were, respectively, 97% and 0.91 (95% confidence interval [95% CI] 0.74–1) at the patient level and 99% and 0.81 (95% CI 0.65–0.96) at the joint level. In 4 patients, at least 1 and as many as 5 PET‐positive joints (score ≥1) were found at baseline. Within 2 years of followup, 9 patients had developed clinical arthritis. This included all 4 patients with positive findings on the 11C‐(R)‐PK11195 scan, who developed clinical arthritis in the hand/wrist region, as identified on PET scans. Of the 5 remaining arthritis patients with negative findings on PET scans, 2 developed arthritis in the hand joints and 3 developed arthritis at locations outside the field of view of the PET scanner.
Conclusion
Subclinical arthritis in ACPA‐positive arthralgia patients could be visualized by 11C‐(R)‐PK11195 PET scanning and was associated with development of arthritis within 2 years of followup. This indicates that 11C‐(R)‐PK11195 PET may be useful in determining arthritis activity in the preclinical phase of RA. |
---|---|
Bibliography: | ark:/67375/WNG-BFN1J096-7 ArticleID:ART30655 istex:156A57D95FA914AA1E9D1C487A3EF36EC8A8E8C9 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0004-3591 2326-5191 1529-0131 2326-5205 |
DOI: | 10.1002/art.30655 |